Table of Contents Author Guidelines Submit a Manuscript
Parkinson’s Disease
Volume 2016, Article ID 9646057, 7 pages
http://dx.doi.org/10.1155/2016/9646057
Research Article

Outlining a Population “at Risk” of Parkinson’s Disease: Evidence from a Case-Control Study

1Neurology, Department of Systems Medicine, University of Rome Tor Vergata, Via Montpellier 1, 00133 Rome, Italy
2IRCCS Fondazione Santa Lucia, Via del Fosso di Fiorano, Rome, Italy
3Psychiatry, Department of Systems Medicine, University of Rome Tor Vergata, Via Montpellier 1, 00133 Rome, Italy

Received 2 May 2016; Revised 26 June 2016; Accepted 28 July 2016

Academic Editor: Jan Aasly

Copyright © 2016 Tommaso Schirinzi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. D. Athauda and T. Foltynie, “The ongoing pursuit of neuroprotective therapies in Parkinson disease,” Nature Reviews Neurology, vol. 11, no. 1, pp. 25–40, 2015. View at Publisher · View at Google Scholar · View at Scopus
  2. A. H. V. Schapira, C. W. Olanow, J. T. Greenamyre, and E. Bezard, “Slowing of neurodegeneration in Parkinson's disease and Huntington's disease: future therapeutic perspectives,” The Lancet, vol. 384, no. 9942, pp. 545–555, 2014. View at Publisher · View at Google Scholar · View at Scopus
  3. F. Stocchi, “Therapy for Parkinson's disease: what is in the pipeline?” Neurotherapeutics, vol. 11, no. 1, pp. 24–33, 2014. View at Publisher · View at Google Scholar · View at Scopus
  4. J. Trinh and M. Farrer, “Advances in the genetics of Parkinson disease,” Nature Reviews Neurology, vol. 9, no. 8, pp. 445–454, 2013. View at Publisher · View at Google Scholar
  5. T. Kitada, J. J. Tomlinson, H. S. Ao, D. A. Grimes, and M. G. Schlossmacher, “Considerations regarding the etiology and future treatment of autosomal recessive versus idiopathic parkinson disease,” Current Treatment Options in Neurology, vol. 14, no. 3, pp. 230–240, 2012. View at Publisher · View at Google Scholar · View at Scopus
  6. C. M. Tanner, “Advances in environmental epidemiology,” Movement Disorders, vol. 25, supplement 1, pp. S58–S62, 2010. View at Publisher · View at Google Scholar
  7. S. Petrucci, F. Consoli, and E. M. Valente, “Parkinson disease genetics: a ‘continuum’ from mendelian to multifactorial inheritance,” Current Molecular Medicine, vol. 14, no. 8, pp. 1079–1088, 2014. View at Publisher · View at Google Scholar · View at Scopus
  8. P. De Rosa, E. S. Marini, V. Gelmetti, and E. M. Valente, “Candidate genes for Parkinson disease: lessons from pathogenesis,” Clinica Chimica Acta, vol. 449, pp. 68–76, 2015. View at Publisher · View at Google Scholar · View at Scopus
  9. A. J. Noyce, A. J. Lees, and A. Schrag, “The prediagnostic phase of Parkinson's disease,” Journal of Neurology, Neurosurgery & Psychiatry, vol. 87, no. 8, pp. 871–878, 2016. View at Publisher · View at Google Scholar
  10. I. Litvan, P. S. J. Lees, C. R. Cunningham et al., “Environmental and occupational risk factors for progressive supranuclear palsy: Case-Control Study,” Movement Disorders, vol. 31, no. 5, pp. 644–652, 2016. View at Publisher · View at Google Scholar · View at Scopus
  11. M. Moccia, R. Erro, M. Picillo et al., “Quitting smoking: an early non-motor feature of Parkinson's disease?” Parkinsonism and Related Disorders, vol. 21, no. 3, pp. 216–220, 2015. View at Publisher · View at Google Scholar · View at Scopus
  12. A. T. Jan, M. Azam, K. Siddiqui, A. Ali, I. Choi, and Q. M. R. Haq, “Heavy metals and human health: mechanistic insight into toxicity and counter defense system of antioxidants,” International Journal of Molecular Sciences, vol. 16, no. 12, pp. 29592–29630, 2015. View at Publisher · View at Google Scholar · View at Scopus
  13. R. J. Ward, F. A. Zucca, J. H. Duyn, R. R. Crichton, and L. Zecca, “The role of iron in brain ageing and neurodegenerative disorders,” The Lancet Neurology, vol. 13, no. 10, pp. 1045–1060, 2014. View at Publisher · View at Google Scholar · View at Scopus
  14. K. M. Davies, J. F. Mercer, N. Chen, and K. L. Double, “Copper dyshomoeostasis in Parkinson's disease: implications for pathogenesis and indications for novel therapeutics,” Clinical Science, vol. 130, no. 8, pp. 565–574, 2016. View at Publisher · View at Google Scholar
  15. S. Bouabid, A. Tinakoua, N. Lakhdar-Ghazal, and A. Benazzouz, “Manganese neurotoxicity: behavioral disorders associated with dysfunctions in the basal ganglia and neurochemical transmission,” Journal of Neurochemistry, vol. 136, no. 4, pp. 677–691, 2016. View at Publisher · View at Google Scholar · View at Scopus
  16. Z. S. Agim and J. R. Cannon, “Dietary factors in the etiology of Parkinson's disease,” BioMed Research International, vol. 2015, Article ID 672838, 16 pages, 2015. View at Publisher · View at Google Scholar · View at Scopus
  17. M. Chin-Chan, J. Navarro-Yepes, and B. Quintanilla-Vega, “Environmental pollutants as risk factors for neurodegenerative disorders: Alzheimer and Parkinson diseases,” Frontiers in Cellular Neuroscience, vol. 9, article A124, 2015. View at Publisher · View at Google Scholar · View at Scopus
  18. H. W. Zhao, J. Lin, X. B. Wang et al., “Assessing plasma levels of selenium, copper, iron and zinc in patients of Parkinson's disease,” PLoS ONE, vol. 8, no. 12, Article ID e83060, 2013. View at Publisher · View at Google Scholar
  19. S. S. S. J. Ahmed and W. Santosh, “Metallomic profiling and linkage map analysis of early Parkinson's disease: a new insight to aluminum marker for the possible diagnosis,” PLoS ONE, vol. 5, no. 6, Article ID e11252, 2010. View at Publisher · View at Google Scholar · View at Scopus
  20. S. Casjens, J. Henry, H.-P. Rihs et al., “Influence of welding fume on systemic iron status,” Annals of Occupational Hygiene, vol. 58, no. 9, pp. 1143–1154, 2014. View at Publisher · View at Google Scholar · View at Scopus
  21. T. Fukushima, X. Tan, Y. Luo, and H. Kanda, “Relationship between blood levels of heavy metals and Parkinson's disease in China,” Neuroepidemiology, vol. 34, no. 1, pp. 18–24, 2010. View at Publisher · View at Google Scholar · View at Scopus
  22. G. Logroscino, X. Gao, H. Chen, A. Wing, and A. Ascherio, “Dietary iron intake and risk of Parkinson's disease,” American Journal of Epidemiology, vol. 168, no. 12, pp. 1381–1388, 2008. View at Publisher · View at Google Scholar · View at Scopus
  23. J. Hagemeier, O. Tong, M. G. Dwyer, F. Schweser, M. Ramanathan, and R. Zivadinov, “Effects of diet on brain iron levels among healthy individuals: an MRI pilot study,” Neurobiology of Aging, vol. 36, no. 4, pp. 1678–1685, 2015. View at Publisher · View at Google Scholar · View at Scopus
  24. T. Konz, J. Alonso-García, M. Montes-Bayón, and A. Sanz-Medel, “Comparison of copper labeling followed by liquid chromatography-inductively coupled plasma mass spectrometry and immunochemical assays for serum hepcidin-25 determination,” Analytica Chimica Acta, vol. 799, pp. 1–7, 2013. View at Publisher · View at Google Scholar · View at Scopus
  25. A. J. Noyce, J. P. Bestwick, L. Silveira-Moriyama et al., “Meta-analysis of early nonmotor features and risk factors for Parkinson disease,” Annals of Neurology, vol. 72, no. 6, pp. 893–901, 2012. View at Publisher · View at Google Scholar · View at Scopus
  26. J. R. Cannon and J. T. Greenamyre, “Gene-environment interactions in Parkinson's disease: specific evidence in humans and mammalian models,” Neurobiology of Disease, vol. 57, pp. 38–46, 2013. View at Publisher · View at Google Scholar · View at Scopus
  27. G. Martella, G. Madeo, M. Maltese et al., “Exposure to low-dose rotenone precipitates synaptic plasticity alterations in PINK1 heterozygous knockout mice,” Neurobiology of Disease, vol. 91, pp. 21–36, 2016. View at Publisher · View at Google Scholar
  28. M. van der Mark, R. Vermeulen, P. C. G. Nijssen et al., “Occupational exposure to solvents, metals and welding fumes and risk of Parkinson's disease,” Parkinsonism and Related Disorders, vol. 21, no. 6, pp. 635–639, 2015. View at Publisher · View at Google Scholar · View at Scopus
  29. http://www.arpalazio.gov.it/.
  30. S. Levesque, M. J. Surace, J. McDonald, and M. L. Block, “Air pollution and the brain: subchronic diesel exhaust exposure causes neuroinflammation and elevates early markers of neurodegenerative disease,” Journal of Neuroinflammation, vol. 8, article 105, 2011. View at Publisher · View at Google Scholar · View at Scopus
  31. C. L. Mumaw, S. Levesque, C. McGraw et al., “Microglial priming through the lung-brain axis: the role of air pollution-induced circulating factors,” The FASEB Journal, vol. 30, no. 5, pp. 1880–1891, 2016. View at Publisher · View at Google Scholar
  32. X. Li, W. Li, G. Liu, X. Shen, and Y. Tang, “Association between cigarette smoking and Parkinson's disease: a meta-analysis,” Archives of Gerontology and Geriatrics, vol. 61, no. 3, pp. 510–516, 2015. View at Publisher · View at Google Scholar
  33. F. Cicchetti, J. Drouin-Ouellet, and R. E. Gross, “Environmental toxins and Parkinson's disease: what have we learned from pesticide-induced animal models?” Trends in Pharmacological Sciences, vol. 30, no. 9, pp. 475–483, 2009. View at Publisher · View at Google Scholar
  34. C. M. Tanner, S. M. Goldman, D. A. Aston et al., “Smoking and Parkinson's disease in twins,” Neurology, vol. 58, no. 4, pp. 581–588, 2002. View at Publisher · View at Google Scholar · View at Scopus
  35. L. Ishihara and C. Brayne, “A systematic review of nutritional risk factors of Parkinson's disease,” Nutrition Research Reviews, vol. 18, no. 2, pp. 259–282, 2005. View at Publisher · View at Google Scholar
  36. S. S. Bettiol, T. C. Rose, C. J. Hughes, and L. A. Smith, “Alcohol consumption and Parkinson's disease risk: a review of recent findings,” Journal of Parkinson's Disease, vol. 5, no. 3, pp. 425–442, 2015. View at Publisher · View at Google Scholar · View at Scopus
  37. A. Iranzo, J. L. Molinuevo, J. Santamaría et al., “Rapid-eye-movement sleep behaviour disorder as an early marker for a neurodegenerative disorder: a descriptive study,” Lancet Neurology, vol. 5, no. 7, pp. 572–577, 2006. View at Publisher · View at Google Scholar · View at Scopus
  38. R. B. Postuma, A. Iranzo, B. Hogl et al., “Risk factors for neurodegeneration in idiopathic rapid eye movement sleep behavior disorder: a multicenter study,” Annals of Neurology, vol. 77, no. 5, pp. 830–839, 2015. View at Publisher · View at Google Scholar · View at Scopus
  39. P. Mahlknecht, A. Iranzo, B. Högl et al., “Olfactory dysfunction predicts early transition to a Lewy body disease in idiopathic RBD,” Neurology, vol. 84, no. 7, pp. 654–658, 2015. View at Publisher · View at Google Scholar · View at Scopus
  40. R. B. Postuma, J.-F. Gagnon, J.-A. Bertrand, D. Génier Marchand, and J. Y. Montplaisir, “Parkinson risk in idiopathic REM sleep behavior disorder: preparing for neuroprotective trials,” Neurology, vol. 84, no. 11, pp. 1104–1113, 2015. View at Publisher · View at Google Scholar · View at Scopus
  41. Y. K. Kim, I.-Y. Yoon, J.-M. Kim et al., “The implication of nigrostriatal dopaminergic degeneration in the pathogenesis of REM sleep behavior disorder,” European Journal of Neurology, vol. 17, no. 3, pp. 487–492, 2010. View at Publisher · View at Google Scholar · View at Scopus
  42. T. Paillard, Y. Rolland, and P. S. de Barreto, “Protective effects of physical exercise in Alzheimer’s disease and Parkinson’s disease: a narrative review,” Journal of Clinical Neurology, vol. 11, no. 3, pp. 212–219, 2015. View at Publisher · View at Google Scholar · View at Scopus
  43. M. Caruana and N. Vassallo, “Tea polyphenols in Parkinson’s disease,” in Natural Compounds as Therapeutic Agents for Amyloidogenic Diseases, N. Vassallo, Ed., vol. 863 of Advances in Experimental Medicine and Biology, pp. 117–137, Springer, Berlin, Germany, 2015. View at Publisher · View at Google Scholar